GlassScriptPhysician profile
Myriam Sterlin
NPI 1902825185
$4,286.87
in general payments reported to CMS, 2019-2025
27 companies · $594 in 2025
The $594 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $295 · 2020: $664 · 2021: $726 · 2022: $652 · 2023: $725 · 2024: $633 · 2025: $594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,951.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,951.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $874.55 | 2019-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $768.66 | 2019-2025 | Arexvy, Nucala, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $421.98 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $373.50 | 2022-2025 | |
| Amarin Pharma, INC. | $314.95 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $244.41 | 2020-2024 | Fasenra, Farxiga |
| Lilly USA, LLC | $198.29 | 2020-2025 | Zepbound, Mounjaro |
| Merck Sharp & Dohme LLC | $190.74 | 2019-2025 | Verquvo, Belsomra, Winrevair |
| Jazz Pharmaceuticals INC. | $123.27 | 2019-2022 | |
| Amgen INC. | $103.70 | 2020-2024 | Repatha, Otezla |
| Pfizer INC. | $102.68 | 2019-2023 | |
| Exact Sciences Corporation | $81.85 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Genzyme Corporation | $64.00 | 2020-2025 | |
| Sunovion Pharmaceuticals INC. | $63.97 | 2020-2021 | |
| Lexicon Pharmaceuticals, INC. | $55.37 | 2023 | Inpefa |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $49.37 | 2021-2023 | Wakix |
| Actelion Pharmaceuticals US, INC. | $46.02 | 2020-2025 | Uptravi |
| Idorsia Pharmaceuticals US INC | $43.61 | 2022-2023 | Quviviq |
| United Therapeutics Corporation | $28.12 | 2021-2023 | Tyvaso |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $26.89 | 2023 | Lifevest |
| Shield Therapeutics INC | $19.59 | 2024 | |
| Inspire Medical Systems, INC. | $18.43 | 2023 | Inspire |
| Mylan Specialty L.P. | $17.70 | 2022 | |
| Abbott Laboratories | $15.36 | 2021 | |
| Alexion Pharmaceuticals, INC. | $14.37 | 2019 | |
| Eisai INC. | $13.37 | 2021 | |
| Cashflow Solutions, LLC | $12.12 | 2024 | Lympha Press Optimal Plus(US) Bt, Pcd-51 731a (US) - White, Pcd-52 737a (US) White |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Myriam Sterlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.